Opendata, web and dolomites

BITCAT SIGNED

Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BITCAT project word cloud

Explore the words cloud of the BITCAT project. It provides you a very rough idea of what is the project "BITCAT" about.

suppression    area    efficacy    advantageous    rna    modulate    bioavailability    expression    induce    skipping    antibodies    utilized    reduce    soluble    clinical    antisense    demonstrated    ex    immunotherapeutics    isoforms    block    arose    mcmaster    vaccines    polyethylenimine    evading    exon    drugs    protein    world    models    escape    immunology    competitive    candidates    class    considerable    genes    renowned    interests    surface    career    immunity    special    oncology    polycationic    systemic    technique    vitro    immune    practical    oligonucleotides    cancer    fraunhofer    tumour    mediated    immunotherapy    receptor    advantages    tissue    potentially    health    toxicity    successful    good    propagating    either    anti    nanoparticles    liposomal    environment    pd    completely    researcher    mechanism    scientific    employment    german    checkpoint    l1    therapy    tumours    genetics    prolific    proper    society    advantage    inhibition    canadian    university    cell    designed    vivo    pto    ctla4    charmingly    antagonistic    tested   

Project "BITCAT" data sheet

The following table provides information about the project.

Coordinator
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. 

Organization address
address: HANSASTRASSE 27C
city: MUNCHEN
postcode: 80686
website: www.fraunhofer.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 243˙352 €
 EC max contribution 243˙352 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-05-08   to  2020-05-07

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) coordinator 243˙352.00
2    MCMASTER UNIVERSITY CA (HAMILTON) partner 0.00

Map

 Project objective

Tumours escape proper immune response by propagating immune suppression. Immunotherapy aims to enhance anti-tumour immunity. This highly relevant research area arose recently from advantages in immunology, genetics and oncology. Currently, immunotherapeutics are either protein (e.g. antibodies) or cell-based (e.g. cancer vaccines) and promising approaches target immune checkpoint control, a mechanism crucial for anti-tumour T cell activity. Here, development of a completely new class of immunotherapeutics based on advantageous oligonucleotides is proposed. To this aim, oligonucleotides will be designed to modulate expression of receptor genes involved in immune checkpoint control (e.g. PD-L1, CTLA4) and thus block tumour-mediated T cell inhibition. Of special interest will be the employment of the exon skipping technique to reduce surface receptor and potentially induce antagonistic soluble isoforms. To ensure delivery of oligonucleotides, liposomal or polycationic nanoparticles will be utilized as previous studies demonstrated good tissue bioavailability, e.g. for PTO-antisense RNA and polyethylenimine. Oligonucleotides will be tested for functionality, efficacy and non-toxicity in vitro. To facilitate practical clinical application of the developed drugs, most promising candidates will then be applied to pre-clinical tumour models in vivo. Charmingly, this novel technique will also be applied ex vivo to enhance anti-cancer cell therapy, thus evading systemic distribution. Collaboration of two world-renowned scientific institutions, the German Fraunhofer society and Canadian partner McMaster University, will ensure a prolific environment for successful project conclusion and allow considerable advancement of the career of a most promising European researcher. Furthermore, the project will support development of a key technology in the important field of cancer therapy, thus providing a significant competitive advantage for European interests in health research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BITCAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BITCAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MultiSeaSpace (2019)

Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.

Read More  

EGeoCC (2019)

Ethnic geography and civil conflict

Read More  

Topo-circuit (2019)

Exploring topological phenomenon in RF circuits

Read More